Extracorporeal Shock Wave Therapy for Hypertrophic Scars

Apirag Chuangsuwanich, MD1  Natthapong Kongkunnavat, MD1  Malika Kamanamool, MD1  Gulradar Maipeng2  Nanticha Kamanamool, MD3  Warangkana Tonaree, MD1

1 Division of Plastic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand  
2 Perioperative Nurse Division, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand  
3 Department of Preventive and Social Medicine, Faculty of Medicine Srinakharinwirot University, Ongkharak, Thailand

Address for correspondence Warangkana Tonaree, MD, Division of Plastic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, BangkokNoi, Bangkok 10700, Thailand (e-mail: Teenybd@gmail.com).

Keywords
► extracorporeal shock wave  
► hypertrophic scar  
► wound healing  
► scar prevention

Abstract

Background  Hypertrophic scars cause aesthetic concerns and negatively affect the quality of life. A gold standard treatment for hypertrophic scars has not been established due to various responses of modalities. Extracorporeal shock wave therapy (ESWT) is a noninvasive and affects scar remodeling by fibroblast regulation. This study investigated the effectiveness of ESWT for hypertrophic scars.

Methods  Twenty-nine patients were enrolled. All patients underwent ESWT once a week for 6 consecutive weeks. Their scars were assessed using the Patient and Observer Scar Assessment Scale (POSAS), erythema index, melanin index, and scar pliability before treatment and again 4 weeks after treatment completion.

Results  Thirty-four hypertrophic scars in this study had persisted for between 6 months and 30 years. Most scars developed after surgical incision (55.88%). The chest and upper extremities were the predominant areas of occurrence (35.29% each). Most of the POSAS subscales and total scores were significantly improved 4 weeks after treatment ($p < 0.05$). Furthermore, the pain, itching, and pigmentation subscale were improved. The pliability, melanin index, and erythema index were also improved, but without significance. The patients were satisfied with the results and symptoms alleviation, although subjective score changes were insignificant. No serious adverse events were found. The patients reported pruritus in 62.5% and good pain tolerance in 37.5%. Subgroup analyses found no differences in scar etiologies or properties at different parts of the body.

Conclusion  The ESWT is a modality for hypertrophic scar treatment with promising results. Most of POSAS subscales were significantly improved.

ISSN 2234-6163.

© 2022. The Korean Society of Plastic and Reconstructive Surgeons. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA.
Introduction

Hypertrophic scar occurs from an abnormal wound healing process that involves excessive dermal collagen production. It may affect patients in several ways, such as pruritic sensation, scar tenderness, and limited range of motion. These negatively impact the quality of life of patients.\(^1\)

The reported incidences of hypertrophic scars following surgical incision wounds ranged from 40 to 70%. However, incidences of up to 90% have been reported after burns, especially in individuals with a higher Fitzpatrick skin tone.\(^2\)

Approximately 1,200 patients seek hypertrophic scar treatment annually at our outpatient plastic surgery department.

Currently, there is no established gold standard for hypertrophic scar treatment since the responses to treatment and recurrence rates have varied. Several treatment modalities have been combined for hypertrophic scar treatment, such as intralesional steroid injections, pressure dressings, surgical excision, pulsed dye lasers, and radiation therapy. However, no combination proved to be successful curative therapy. Furthermore, most modalities require multiple treatment sessions and have adverse effects associated with their use. Therefore, a noninvasive treatment modality with good efficacy could be a preferable treatment option.\(^2,3\)

Extracorporeal shock wave therapy (ESWT) has been widely used as a noninvasive and well-tolerated treatment for tendinopathy in general. It is also used for other orthopaedic diseases, nephroureterolithiasis, ischemic cardiovascular disease, burn wound scars, acute and chronic wounds. The wide range of applications highlights the versatile benefits and regenerative potential of ESWT.\(^4\)–\(^11\) ESWT transmits a mechanical force via an acoustic wave to facilitate wound healing. The force stimulates the release of neuropeptides from nerve endings and improves wound healing. Furthermore, it also stimulates fibroblasts, which are mechanoresponsive cells and play a role in remodeling of the extracellular matrix in wound healing and scars.\(^12\)–\(^20\)

The molecular mechanism of ESWT has not yet been fully identified. However, induction of angiogenesis via stimulation of toll-like receptor 3 during ESWT was proposed in the literatures, possibly indicating the benefits of soft tissue regeneration.\(^21,22\) In the research by Fioramonti et al, the effectiveness of ESWT for burn scars was found to be promising, with no adverse events observed.\(^4\) This study aimed to investigate the effectiveness of ESWT for hypertrophic scars.

Methods

Study Design

This study was approved by the Institutional Review Board (approval number 295/2016). The Declaration of Helsinki protocol was followed. The study was conducted at the outpatient department of plastic surgery unit from September 2016 to November 2017. Twenty-nine patients were enrolled and gave written informed consent.

Patients aged between 18 and 75 years old and had persistent hypertrophic scars for more than 6 months prior to the study were included. Exclusion criteria were a history of hypertrophic scar-related treatment within 2 months prior to enrolment; conditions or risk factors for impaired wound healing (such as an immunocompromised state, connective tissue disease, and smoking); a concurrent active systemic infection; and pregnancy.

Study Protocol

ESWT was performed once a week for 6 consecutive weeks by using Dermagold 100 (MTS Europe GmbH, Konstanz, Germany). The settings were 0.1 ml/mm\(^2\) energy, 4 Hz frequency, and 350 pulses +10 pulses/cm\(^2\).

At 4 weeks after completion of treatment, hypertrophic scars were reassessed with the POSAS, the erythema index and the melanin index; evaluation of scar pliability; and photographic documentation (Fig. 1).

Hypertrophic Scar Evaluation

Hypertrophic scars were evaluated with POSAS, a validated assessment tool for scar treatment. It consists of two
The patient scar assessment scale includes pain, pruritic sensation, dyspigmentation, pliability, thickness, irregularity, and overall opinion of scar. The parameters in observer scar assessment scale consist of vascularity, pigmentation, thickness, relief, pliability, and surface area.

To assess the physical properties of scars, their areas were measured using the widest part of each scar as the scar width and the most extended section as the scar length. In addition, the thickness of the scars was measured three times to establish the average value of the thickest part of each scar. The measurement points were noted, and the calculations at subsequent visits used the same points. The same portion of each scar was documented, measured, and evaluated before and after each ESWT session to ensure that comparisons were accurate.

The erythema and melanin indices were measured with a Mexameter MX 18 (Courage + Khazaka Electronic GmbH, Cologne, Germany). The erythema index has an arbitrary number of 0 to 999. The higher the value is, the greater the degree of erythema present. The melanin index also has a scale number and a similar interpretation guide. The greater the melanin index value is, the greater the melanin content present.

For the scar pliability, the Cutometer dual MPA 580 (Courage + Khazaka Electronic GmbH, Cologne, Germany) was used. The elasticity index of the R2 parameter represents the gross elasticity of a hypertrophic scars. It is one of the most widely used parameters in the literatures.

Statistical Analysis
The primary outcome was the improvement in hypertrophic scars, indicated by the POSAS. All other results were defined as secondary outcomes. To estimate the sample size, we relied on the work of Fioramonti et al. The sample size was calculated using the PS Power and Sample Size Calculation program at an α level of 0.05, a maximum tolerated error of 0.15, and a 10% dropout. According to the calculation, 30 patients were needed. A paired t-test was used for continuous data in the subgroup analyses.

All statistical data were analyzed by PASW Statistics for Windows, version 18.0 (SPSS Inc., Chicago, IL). A p-value less than 0.05 was considered statistically significant.

Results
Twenty-nine patients with 34 hypertrophic scars were enrolled. Their average age was 42.06 ± 15.57 years. The scars had persisted for between 6 months and 30 years. Most had developed after surgical incision wounds (55.88%) following by traumatic wounds (20.59%), burn wounds (11.76%), and infected wounds (11.76%). The chest and upper extremities were the main areas of scar occurrence (each was 35.29%), followed by the face, abdomen, and lower extremities (each was 8.82%; Table 1). The surgical incision wounds and traumatic wounds were all closed primarily. Burn wounds were healed by secondary intention or skin grafts if indicated. The infected wounds were healed by delayed primary closure or secondary intention if indicated.

At 4 weeks after completion of treatment, almost of POSAS subscales and total scores had improved from both the patients’ and observers’ aspects. The scar color, scar stiffness, scar thickness, scar irregularity, overall scar, and total score of POSAS patient scale were significantly improve (p < 0.01). Improvements were also observed in the pain and pruritic subscale of POSAS patient scale, but the differences were not statistically significant (p = 0.66 and 0.34, respectively). The scar vascularity, scar thickness, relief, pliability, and total score of POSAS observer scale were significantly improved (p < 0.01). The observer-evaluated surface area improvement in POSAS observer scale was also significantly improved (p < 0.05). However, the observer-evaluated scar pigmentation also displayed improvement without significance (p = 0.09) (Table 2).

For the physical properties of the scars, the pliability (represented by the R2 parameter) improved from 0.61 ± 0.02 to 0.63 ± 0.02 (p = 0.48). Likewise, the melanin index improved from 285.65 ± 24.88 to 283.83 ± 23.24 (p = 0.87). Although the erythema index also improved from 439.18 ± 14.92 to 435.16 ± 14.74, the difference was
The scar area went up from 24.83 ± 6.58 cm² to 25.25 ± 6.74 cm², and the thickness rose from 0.81 ± 0.20 cm to 0.84 ± 0.26 cm. However, neither increase was statistically significant (p = 0.60 and 0.88, respectively; ►Figs. 2 and 3).

Adverse events, which were short-term temporary symptoms occurring only during ESWT sessions, were found in 23.5% of the cases. About 62.5% of the patients experienced the pruritic sensation when applied the ESWT to the hypertrophic scars and well-tolerated pain was reported by 37.5% of patients during application of ESWT. No serious adverse effects were found.

Subgroup analyses were performed to compare the etiology of scars and differences by the location on the body. The POSAS, scar pliability, melanin index, and erythema index of each subgroup were compared. There was no statistically significant difference in the etiology of scars resulting from surgical and nonsurgical wounds. Additionally, the hypertrophic scar properties were not different between body locations (chest and back versus other areas). The subgroup analysis data are detailed in ►Supplementary Table S1 (available in the online version).

**Table 2** Comparison of the results of the parameters of the hypertrophic scars

<table>
<thead>
<tr>
<th></th>
<th>Before treatment (mean ± SD)</th>
<th>After treatment (mean ± SD)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POSAS patient scale</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain sensation</td>
<td>4.41 ± 0.43</td>
<td>4.16 ± 0.48</td>
<td>0.66</td>
</tr>
<tr>
<td>Pruritic sensation</td>
<td>5.53 ± 0.38</td>
<td>5.03 ± 0.49</td>
<td>0.34</td>
</tr>
<tr>
<td>Scar color</td>
<td>8.00 ± 0.37</td>
<td>5.40 ± 0.44</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Scar stiffness</td>
<td>7.88 ± 0.37</td>
<td>5.31 ± 0.45</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Scar thickness</td>
<td>8.00 ± 0.33</td>
<td>6.06 ± 0.45</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Surface irregularity</td>
<td>8.09 ± 0.41</td>
<td>6.22 ± 0.44</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Overall scar</td>
<td>9.00 ± 0.28</td>
<td>6.22 ± 0.48</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Total score</td>
<td>49.36 ± 2.20</td>
<td>38.42 ± 2.43</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>POSAS observer scale</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scar vascularity</td>
<td>5.18 ± 0.41</td>
<td>3.35 ± 0.35</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Scar pigmentation</td>
<td>3.18 ± 0.31</td>
<td>2.76 ± 0.31</td>
<td>0.09</td>
</tr>
<tr>
<td>Scar thickness</td>
<td>5.41 ± 0.39</td>
<td>4.38 ± 0.36</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Relief</td>
<td>4.94 ± 0.41</td>
<td>3.76 ± 0.30</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Pliability</td>
<td>5.38 ± 0.36</td>
<td>4.24 ± 0.35</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Surface area</td>
<td>4.56 ± 0.37</td>
<td>3.94 ± 0.27</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Total score</td>
<td>28.65 ± 1.49</td>
<td>22.44 ± 1.52</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Physical properties</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R² parameter</td>
<td>0.61 ± 0.02</td>
<td>0.63 ± 0.02</td>
<td>0.48</td>
</tr>
<tr>
<td>Melanin index</td>
<td>285.65 ± 24.88</td>
<td>283.83 ± 23.24</td>
<td>0.87</td>
</tr>
<tr>
<td>Erythema index</td>
<td>439.18 ± 14.92</td>
<td>435.16 ± 14.74</td>
<td>0.70</td>
</tr>
<tr>
<td>Scar area (cm²)</td>
<td>24.83 ± 6.58</td>
<td>25.25 ± 6.74</td>
<td>0.60</td>
</tr>
<tr>
<td>Scar thickness (cm)</td>
<td>0.81 ± 0.20</td>
<td>0.84 ± 0.26</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>8 (23.53%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritic sensation</td>
<td>5 (62.50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well-tolerated pain</td>
<td>3 (37.50%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: POSAS, Patient and Observer Scar Assessment Scale; SD, standard deviation.

*Nearly all results of POSAS subscales were statistically significantly improved (p < 0.05).
has not yet been established. Furthermore, current treatments have adverse events associated with their use. An ideal properties of hypertrophic scar treatment should be easy-to-use, noninvasive, well-tolerated, available at outpatient setting, and less adverse events. ESWT meets all of these attributes. ESWT is a noninvasive modality for hypertrophic scar treatment. Although its mechanism of action is still under investigation, complex biological responses are known to be activated by ESWT. Among them are the release of growth factors, cytokines, and chemokines, and the regulation of fibroblasts. These responses lead to wound and scar remodeling.

Fioramonti et al examined the use of ESWT for hypertrophic scars following burn wounds. The researchers found an improvement in the visual analog scales used for scar assessment. However, as the scores of visual analog scale represent subjective evaluations, they vary with the observer. In this study, we used both subjective and objective evaluations. The POSAS, which is validated scale in both patient and observer aspect, was used for subjective evaluation. To evaluate hypertrophic scars objectively, we used a Cutometer for pliability evaluations and Mexameter to assess melanin and erythema indices. The results showed a significant improvement in almost all POSAS subscales for both the patient and observer aspects, but no significant improvements in size, thickness, scar pliability, and erythema and melanin indices. The underlying cause of the nonsignificant improvements in some parameters could be the effect of the irregularity of the scar surface, confounding the results.

In addition, there were several studies about the mechanism of improvement in hypertrophic scars after ESWT. We transformed the effects of ESWT on hypertrophic scars into the clinical results as POSAS scores, and most of the POSAS subscales were significantly improved after treatment. Apart from the previous studies, which included only the hypertrophic scars following burn wounds, the current study also included the various etiologies of hypertrophic scars to extend the indications of using ESWT in other causes of hypertrophic scars.

For further study improvement, errors in area measurements might be resolved using a computer-assisted method. The use of ultrasound might also reduce thickness measurement errors. Ultrasound is consistent due to its accuracy and reproducibility.

As to the nature of hypertrophic scars, some parts of the scars had more stiffness than the surrounding skin, whereas other parts demonstrated more noticeable deformation than the nearby skin. Heterogeneity within lesions results in lower reliability of scar pliability measurements. Results might not represent the properties of the whole scar, leading to inconsistent measurements.

**Fig. 2** Improvement in a hypertrophic scar after extracorporeal shock wave therapy (ESWT). The hypertrophic scar at the right jawline; note the redness, vascularity, and thickness before treatment (A). Improvement in redness, vascularity, and thickness of the hypertrophic scar 4 weeks after the completion of ESWT (B).

**Fig. 3** Improvement in a hypertrophic scar after extracorporeal shock wave therapy (ESWT). The hypertrophic scar had erythema and hyperpigmentation at before treatment (A). Improvement in erythema and hyperpigmentation of the hypertrophic scar 4 weeks after the completion of ESWT (B).
This study observed outcomes 4 weeks after treatment. However, this time point might not capture the maximum efficacy or long-term effects of hypertrophic scar treatment with ESWT. Further research on the long-term effects might be considered.

In conclusion, ESWT demonstrated promising improvements in hypertrophic scars, as evaluated by POSAS. This study served as support data for further investigations of the use of ESWT for the treatment of hypertrophic scars.

Author Contributions

Ethical Approval
This study was approved by the Institutional Review Board of Faculty of Medicine Siriraj Hospital (approval number 295/2016). The Declaration of Helsinki protocol was followed.

Patient Consent
Informed consent was obtained from all individual participants included in the study.

Conflict of Interest
A.C. is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

References
29 Neto P, Ferreira M, Bahia F, Costa P. Improvement of the methods for skin mechanical properties evaluation through correlation